89bio

Biotechnology ResearchCalifornia, United States51-200 Employees

89bio is a biotechnology research company headquartered in San Francisco, California, United States, employing 51-200 people. In September 2025, the company was acquired by Roche and became part of the Roche Group, integrated into Roche Pharmaceuticals Division. It develops pegozafermin, an FGF21 analogue, which is in Phase 3 trials for metabolic liver and cardiometabolic conditions, specifically Metabolic Dysfunction-Associated Steatohepatitis and severe hypertriglyceridemia. 89bio operates in the biotechnology research industry and maintains a corporate website at https://89bio.com. The company reports revenue in the range of $50 million to $100 million and has funding of $288 million.

Sign up for free to view info

Email Format Employee directory